Therapeutic
reactivation of the γ-globin genes for fetal
hemoglobin (HbF) production is an attractive strategy for treating
β-thalassemia and sickle cell disease. It was reported that
genetic knockdown of the histone lysine methyltransferase EHMT2/1
(G9a/GLP) is sufficient to induce HbF production. The aim of the present
work was to acquire a G9a/GLP inhibitor that induces HbF production
sufficiently. It was revealed that tetrahydroazepine has versatility
as a side chain in various skeletons. We ultimately obtained a promising
aminoindole derivative (DS79932728), a potent and orally bioavailable
G9a/GLP inhibitor that was found to induce γ-globin production
in a phlebotomized cynomolgus monkey model. This work could facilitate
the development of effective new approaches for treating β-thalassemia
and sickle cell disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.